Transcenta Therapeutics and WuXi Biologics announced a licensing collaboration to accelerate commercialization of Transcenta’s intensified continuous bioprocessing (HiCB) technology and ExcelPro cell culture media. The deal includes an upfront payment and milestone eligibility, with WuXi positioned as a strategic partner for CMC development and supporting molecules across Transcenta’s pipeline. Separately, Kura Oncology launched Caspian Therapeutics with $50 million in financing led by BVF Partners, with Eli Lilly participating. Caspian will advance KO-7246, a menin inhibitor, through IND-enabling studies for diabetes, aiming to move a chronic-metabolic mechanism toward the clinic. Both items reflect how process innovation and target-differentiated metabolic programs are attracting capital and industrial collaboration as commercialization timelines tighten.